Zobrazeno 1 - 10
of 225
pro vyhledávání: '"Pedro Pérez‐Segura"'
Autor:
María del Mar Noblejas-López, Elena García-Gil, Pedro Pérez-Segura, Atanasio Pandiella, Balázs Győrffy, Alberto Ocaña
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Regulatory T cells (Tregs) is a subtype of CD4+ T cells that produce an inhibitory action against effector cells. In the present work we interrogated genomic datasets to explore the transcriptomic profile of breast tumors with high expressio
Externí odkaz:
https://doaj.org/article/74224a059ba148d49dfab9e6ca39f072
Autor:
Silvia Sánchez-Ramón, MD, PhD, Jesús Fuentes-Antrás, MD, Nicholas L. Rider, MD, Pedro Pérez-Segura, MD, PhD, Eduardo de la Fuente-Muñoz, MD, Miguel Fernández-Arquero, PhD, Esmeralda Neves, MD, Rebeca Pérez de Diego, PhD, Alberto Ocaña, MD, PhD, Kissy Guevara-Hoyer, MD, PhD
Publikováno v:
Journal of Allergy and Clinical Immunology: Global, Vol 3, Iss 2, Pp 100203- (2024)
Background: Gastric cancer (GC) stands as a prominent cause of cancer-related mortality and ranks second among the most frequently diagnosed malignancies in individuals with common variable immunodeficiency (CVID). Objective: We sought to conduct a c
Externí odkaz:
https://doaj.org/article/999d1c18df1e4ce0b69c419d841eeff7
Autor:
Alfonso López de Sá, Cristina Díaz-Tejeiro, Elisa Poyatos-Racionero, Cristina Nieto-Jiménez, Lucía Paniagua-Herranz, Adrián Sanvicente, Emiliano Calvo, Pedro Pérez-Segura, Víctor Moreno, Francisco Moris, Alberto Ocana
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-13 (2023)
Abstract Antibody–drug conjugates (ADCs) have emerged as a novel therapeutic strategy that has successfully reached patient treatment in different clinical scenarios. ADCs are formed by an antibody against a specific tumor-associated antigen (TAA),
Externí odkaz:
https://doaj.org/article/c72087b5dfa54ed0aa029fccbd8b25e2
Autor:
Esther Cabañas Morafraile, Cristina Saiz-Ladera, Cristina Nieto-Jiménez, Balázs Győrffy, Adam Nagy, Guillermo Velasco, Pedro Pérez-Segura, Alberto Ocaña
Publikováno v:
Current Oncology, Vol 30, Iss 3, Pp 2569-2581 (2023)
Despite the impressive results obtained with immunotherapy in several cancer types, a significant fraction of patients remains unresponsive to these treatments. In colorectal cancer (CRC), B-RafV600 mutations have been identified in 8–15% of the pa
Externí odkaz:
https://doaj.org/article/e41c2709dfde49eaa725839de2ad6b27
Autor:
Adrián Sanvicente, Cristina Díaz-Tejeiro, Cristina Nieto-Jiménez, Lucia Paniagua-Herranz, Igor López Cade, Győrffy Balázs, Víctor Moreno, Pedro Pérez-Segura, Emiliano Calvo, Alberto Ocaña
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 7, p 3987 (2024)
Immuno-oncology has gained momentum with the approval of antibodies with clinical activities in different indications. Unfortunately, for anti-PD (L)1 agents in monotherapy, only half of the treated population achieves a clinical response. For other
Externí odkaz:
https://doaj.org/article/6cdddf10de4345e7aa95611bb8650b3a
Autor:
Cristina Nieto‐Jiménez, Adrián Sanvicente, Cristina Díaz‐Tejeiro, Víctor Moreno, Alfonso lopez deSá, Emiliano Calvo, Joaquín Martínez‐López, Pedro Pérez‐Segura, Alberto Ocaña
Publikováno v:
Clinical and Translational Medicine, Vol 13, Iss 9, Pp n/a-n/a (2023)
Abstract Introduction Antibody‐drug conjugates (ADCs) are a family of therapeutic agents that have demonstrated clinical activity in several indications. Material and methods In this article, we performed a deep analysis of their clinical landscape
Externí odkaz:
https://doaj.org/article/445511a833964204a594eaf0a23f9c5e
Autor:
Kissy Guevara-Hoyer, Jesús Fuentes-Antrás, Eduardo de la Fuente-Muñoz, Miguel Fernández-Arquero, Fernando Solano, Pedro Pérez-Segura, Esmeralda Neves, Alberto Ocaña, Rebeca Pérez de Diego, Silvia Sánchez-Ramón
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Common variable immunodeficiency (CVID) represents the largest group of primary immunodeficiencies that may manifest with infections, inflammation, autoimmunity, and cancer, mainly B-cell non-Hodgkin’s lymphoma (NHL). Indeed, NHL may result from ch
Externí odkaz:
https://doaj.org/article/2718f588ad8a45d9b1561b440fdc8138
Autor:
Jesús Fuentes-Antrás, Ana Martínez-Rodríguez, Kissy Guevara-Hoyer, Igor López-Cade, Víctor Lorca, Alejandro Pascual, Alicia de Luna, Carmen Ramírez-Ruda, Jennifer Swindell, Paloma Flores, Ana Lluch, David W. Cescon, Pedro Pérez-Segura, Alberto Ocaña, Frederick Jones, Fernando Moreno, Vanesa García-Barberán, José Ángel García-Sáenz
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 14, p 11419 (2023)
Endocrine-resistant, hormone receptor-positive, and HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) is largely governed by acquired mutations in the estrogen receptor, which promote ligand-independent activation, and by truncal alterations i
Externí odkaz:
https://doaj.org/article/ad6deb7e9e48410696732803de1a58c1
Autor:
Francisco Javier Candel, Pablo Barreiro, Miguel Salavert, Alfonso Cabello, Mario Fernández-Ruiz, Pedro Pérez-Segura, Jesús San Román, Juan Berenguer, Raúl Córdoba, Rafael Delgado, Pedro Pablo España, Ignacio Alberto Gómez-Centurión, Juan María González del Castillo, Sarah Béatrice Heili, Francisco Javier Martínez-Peromingo, Rosario Menéndez, Santiago Moreno, José Luís Pablos, Juan Pasquau, José Luis Piñana, on behalf of the MODUS Investigators (Adenda)
Publikováno v:
Viruses, Vol 15, Iss 7, p 1449 (2023)
The clinical evolution of patients infected with the Severe Acute Respiratory Coronavirus type 2 (SARS-CoV-2) depends on the complex interplay between viral and host factors. The evolution to less aggressive but better-transmitted viral variants, and
Externí odkaz:
https://doaj.org/article/45b1da184dad45e39a6e9199a97d3d53
Autor:
Juan A. Marín-Jiménez, Marc Oliva, Paloma Peinado Martín, Santiago Cabezas-Camarero, Maria Plana Serrahima, Gonzalo Vázquez Masedo, Alicia Lozano Borbalas, María N. Cabrera Martín, Anna Esteve, María C. Iglesias Moreno, Esther Vilajosana Altamis, Lorena Arribas Hortigüela, Miren Taberna Sanz, Pedro Pérez-Segura, Ricard Mesía
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
ObjectivesInduction chemotherapy (ICT) followed by definitive treatment is an accepted non-surgical approach for locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). However, ICT remains a challenge for cisplatin-unfit patients.
Externí odkaz:
https://doaj.org/article/9d6af13842bf47e6b926fa2e5a09c1cc